Flavin-containing monooxygenase 3 as a potential player in diabetes-associated atherosclerosis
Open accessThe DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Abstract
Despite the well-documented association between insulin resistance and cardiovascular disease, the key targets of insulin relevant to the development of cardiovascular disease are not known. Here, using non-biased profiling methods, we identify the enzyme flavin-containing monooxygenase 3 ( Fmo3 ) to be a target of insulin. FMO3 produces trimethylamine N-oxide (TMAO), which has recently been suggested to promote atherosclerosis in mice and humans. We show that FMO3 is suppressed by insulin in vitro , increased in obese/insulin resistant male mice and increased in obese/insulin-resistant humans. Knockdown of FMO3 in insulin-resistant mice suppresses FoxO1, a central node for metabolic control, and entirely prevents the development of hyperglycaemia, hyperlipidemia and atherosclerosis. Taken together, these data indicate that FMO3 is required for FoxO1 expression and the development of metabolic dysfunction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Insights into the mechanisms through which the meta-organismal pathway responsible for TMAO production are associated with enhanced CVD risks have thus far focused on the involvement of TMAO and FMO3 in atherosclerotic plaque development, altered sterol and glucose metabolism, and changes in macrophage phenotype (Wang et al., 2011 ; Koeth et al., 2013; Miao et al., 2015 ; Shih et al., 2015; War”
From Gut Microbial Metabolite TMAO Enhances Platelet Hyperreactivity and Thrombosis Risk (2016) · cites this paper as Miao et al., 2015
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Knockdown of FMO3 in LIRKO mice suppressed FoxO1 expression (and improved glucose tolerance) by upregulating sterol regulatory element binding protein 2 (SREBP2) (77).”
From Trimethylamine N -Oxide, the Microbiome, and Heart and Kidney Disease (2017) · cites this paper as [77]
In the citing paper
“suppression of the host enzyme, FMO3, through antisense oligonucleotide-based approach, results in reduction of both circulating TMAO levels and diet-enhanced atherosclerosis in animal models”
From Non-lethal Inhibition of Gut Microbial Trimethylamine Production for the Treatment of Atherosclerosis (2015) · cites this paper as Miao et al., 2015
In the citing paper
“Taken together, these data suggest that FMO3, which is differentially regulated in male and female mice, is necessary but apparently not sufficient for the development of the diabetic phenotype.”
From Implication of Trimethylamine N-Oxide (TMAO) in Disease: Potential Biomarker or New Therapeutic Target (2018) · cites this paper as [76]
In the citing paper
“downregulation or knock-out of FMO3 leads to decreased levels of TMAO and it is athero-protective in these models, whereas increased expression of FMO3 leads to pro-atherogenic lipid profiles (e.g., higher VLDL and LDL) [75,76].”
From Implication of Trimethylamine N-Oxide (TMAO) in Disease: Potential Biomarker or New Therapeutic Target (2018) · cites this paper as [76]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease
Wang, Z., Klipfell, E., Bennett, B. J., Koeth, R., Levison, B. S., DuGar, B., Feldstein, A. E., Britt, E. B., Fu, X., Chung, Y.-M., et al. (2011) · Nature · doi:10.1038/nature09922 · Cited by 5,597
affy—analysis of Affymetrix GeneChip data at the probe level
Gautier, L., Cope, L., Bolstad, B. M., & Irizarry, R. A. (2004) · Bioinformatics · doi:10.1093/bioinformatics/btg405 · Cited by 5,218
SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15593 · Cited by 4,794
Cardiovascular Morbidity and Mortality Associated With the Metabolic Syndrome
Isomaa, B., Almgren, P., Tuomi, T., Forsén, B., Lahti, K., Nissén, M., Taskinen, M.-R., & Groop, L. (2001) · Diabetes Care · doi:10.2337/diacare.24.4.683 · Cited by 4,760
Intestinal microbiota metabolism of l-carnitine, a nutrient in red meat, promotes atherosclerosis
Koeth, R. A., Wang, Z., Levison, B. S., Buffa, J. A., Org, E., Sheehy, B. T., Britt, E. B., Fu, X., Wu, Y., Li, L., et al. (2013) · Nature Medicine · doi:10.1038/nm.3145 · Cited by 4,386
SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215593 · Cited by 4,092
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk
Tang, W. H. W., Wang, Z., Levison, B. S., Koeth, R. A., Britt, E. B., Fu, X., Wu, Y., & Hazen, S. L. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1109400 · Cited by 3,400
Grundy, S. M., Benjamin, I. J., Burke, G. L., Chait, A., Eckel, R. H., Howard, B. V., Mitch, W., Smith, S. C., & Sowers, J. R. (1999) · Circulation · doi:10.1161/01.cir.100.10.1134 · Cited by 2,698
The Metabolic Syndrome: Time for a Critical Appraisal
Kahn, R., Buse, J., Ferrannini, E., & Stern, M. (2005) · Diabetes Care · doi:10.2337/diacare.28.9.2289 · Cited by 2,378
Research works printed but not linked: 2
- Shih, D. M. et al. Flavin containing monooxygenase 3 exerts broad effects on glucose and lipid metabolism and atherosclerosis. J Lipid Res 56, 22–37 (2015) . · DOI · Paper page
- Roberts, L. D., Souza, A. L., Gerszten, R. E. & Clish, C. B. Curr. Protoc. Mol. Biol eds Frederick M. A.et al. Chapter 30, Unit 30 32 31-24 (2012) .
Cited by
Items 201–300 of 372
Li, X., Zhen, M., Zhou, C., Yu, M., Liu, L., Shu, C., & Wang, C. (2022) · Nano Today · doi:10.1016/j.nantod.2022.101541 · Cited by 21
Huang, Y., Zhang, J., Zhang, Y., Wang, W., Li, M., Chen, B., Zhang, X., Zhang, Z., Huang, J., Jin, Y., et al. (2024) · Liver International · doi:10.1111/liv.15860 · Cited by 22
“49,50 In our study,”
Liu, J., Ge, P., Luo, Y., Sun, Z., Luo, X., Li, H., Pei, B., Xun, L., Zhang, X., Jiang, Y., et al. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s512207 · Cited by 24
Liu, M., Shi, W., Huang, Y., Wu, Y., & Ke-ming, W. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1134430 · Cited by 24
Battillo, D. J., & Malin, S. K. (2023) · Nutrients · doi:10.3390/nu15061455 · Cited by 21
“Further, FMO3 action in the liver mediates the oxidation of TMA to TMAO and is influenced at least in part by liver insulin sensitivity [41].”
BackgroundZheng, C.-W., Luo, Y., Lai, Y. S., Ilhan, Z. E., Ontiveros‐Valencia, A., Krajmalnik‐Brown, R., Jin, Y., Gu, H., Long, X., Zhou, D., et al. (2023) · Water Research · doi:10.1016/j.watres.2023.120738 · Cited by 20
Neyer, P. J., Bernasconi, L., Fuchs, J. A., Allenspach, M., & Steuer, C. (2019) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.23062 · Cited by 20
Lopez, M. F., Zheng, L., Miao, J., Gali, R. R., Górski, G. K., & Hirschhorn, J. N. (2018) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00048.2018 · Cited by 22
Self-citationGut Microbiota-Derived Metabolites and Cardiovascular Disease: Focus on Trimethylamine- N -oxide
He, M., Tan, C. P., & Liu, Y. (2025) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.5c08378 · Cited by 21
Winter, M., Bretschneider, T., Thamm, S., Kleiner, C., Grabowski, D., Chandler, S., Ries, R., Kley, J. T., Fowler, D., Bartlett, C., et al. (2019) · SLAS DISCOVERY · doi:10.1177/2472555219838216 · Cited by 19
Endogenous Roles of Mammalian Flavin-Containing Monooxygenases
Phillips, I. R., & Shephard, E. A. (2019) · Catalysts · doi:10.3390/catal9121001 · Cited by 19
“One study identified FMO3 as a target for down-regulation by insulin [97], indicating that the protein had a detrimental effect.”
BackgroundGut Microbiota and Heart, Vascular Injury
Zeng, C., & Tan, H. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-2385-4_8 · Cited by 21
Moreira Gobis, M. D. L., Goulart de Souza-Silva, T., & de Almeida Paula, H. A. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122741 · Cited by 18
Zhu, B., Ren, H., Xie, F., An, Y., Wang, Y., & Tan, Y. (2022) · Current Pharmaceutical Design · doi:10.2174/1381612828666220919085019 · Cited by 19
Chen, Z., Zhu, Q., Xu, H., Hu, Y., Wang, Y., Chen, Z., Wang, Y., Huang, X., Fu, G., Ma, B., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-66448-7 · Cited by 19
“Therewasevidencepointing out thatinsulinresistancecaused by high TMAO levels might increasethe expression of FMO3, whichsupported our fi ndings 11,17,42 .”
Liu, J., Zhou, S., Wang, Y., Liu, J., Sun, S., Sun, Y., Xu, P., Xu, X., Zhu, B., & Wu, H. (2023) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2023.116604 · Cited by 20
Cho, C. E., Taesuwan, S., Malysheva, O., Bender, E. L., Yan, J., & Caudill, M. A. (2016) · Clinical Nutrition Experimental · doi:10.1016/j.yclnex.2016.10.002 · Cited by 18
Relationship between serum trimethylamine N-oxide and exposure to dioxin-like pollutants
Petriello, M. C., Charnigo, R. J., Sunkara, M., Soman, S., Pavúk, M., Birnbaum, L. S., Morris, A. J., & Hennig, B. (2018) · Environmental Research · doi:10.1016/j.envres.2018.01.007 · Cited by 18
“In a mouse model of insulin resistance, loss of FMO3 protects against hyperglycemia, hyperlipidemia, and atherosclerosis (Miao et al., 2015).”
Hu, Y., Semova, I., Sun, X., Kang, H. M., Chahar, S., Hollenberg, A. N., Masson, D., Hirschey, M. D., Miao, J., & Biddinger, S. B. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.782557 · Cited by 18
“Hepatic lipids were extracted using the Folch method (55, 56).”
MethodSelf-citationProkopienko, A. J., West, R. E., Schrum, D. P., Stubbs, J. R., Leblond, F. A., Pichette, V., & Nolin, T. D. (2019) · Scientific Reports · doi:10.1038/s41598-019-52032-9 · Cited by 17
Zhu, X., Zhao, L., Wang, Y., Hu, X., Zhu, Y., & Yang, X. (2022) · Journal of Hazardous Materials · doi:10.1016/j.jhazmat.2022.129179 · Cited by 18
Xu, S., Liu, Y., Hu, R., Wang, M., Stöhr, O., Xiong, Y., Chen, L., Kang, H., Zheng, L., Cai, S., et al. (2021) · eLife · doi:10.7554/elife.57462 · Cited by 18
Self-citationWilson, S. M. G., Peach, J. T., Fausset, H., Miller, Z. J., Walk, S. T., Yeoman, C. J., Bothner, B. B., & Miles, M. P. (2023) · Frontiers in Nutrition · doi:10.3389/fnut.2023.1244692 · Cited by 17
Hobson, S., de Loor, H., Kublickiene, K. R., Beige, J., Evenepoel, P., Stenvinkel, P., & Ebert, T. (2022) · Toxins · doi:10.3390/toxins14060412 · Cited by 16
“In accordance, inhibiting TMAO production by a knockdown of hepatic flavin-containing monooxygenase 3 entirely prevents the development of dyslipidemia and atherosclerosis in mice [33].”
BackgroundEmerging roles of xenobiotic detoxification enzymes in metabolic diseases
Petriello, M. C., Hoffman, J. B., Morris, A. J., & Hennig, B. (2016) · Reviews on Environmental Health · doi:10.1515/reveh-2016-0050 · Cited by 19
“Additionally, it was shown that FMO3 can be inhibited by insulin in vitro, and FMO3 expression was increased in obese/insulin-resistant clinical patients (7).”
BackgroundInfluentialGutiérrez‐Repiso, C., Moreno‐Indias, I., Martín‐Núñez, G. M., Ho‐Plagaro, A., Rodríguez‐Cañete, A., Gonzalo, M., García‐Fuentes, E., & Tinahones, F. J. (2020) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2020.04.008 · Cited by 20
Mirzababaei, A., Mahmoodi, M. S., Keshtkar, A., Ashraf, H., Abaj, F., Soveid, N., Hajmir, M. M., Radmehr, M., Khalili, P., & Mirzaei, K. (2024) · Frontiers in Nutrition · doi:10.3389/fnut.2024.1326782 · Cited by 15
“Meanwhile, insulin signaling suppresses flavin-containing monooxygenase 3 (FMO3), which is the enzyme that produces TMAO (51).”
BackgroundInfluentialCatucci, G., Aramini, D., Sadeghi, S. J., & Gilardi, G. (2020) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2020.08.032 · Cited by 15
A benzoxazole derivative as an inhibitor of anaerobic choline metabolism by human gut microbiota
Gabr, M. T., Machalz, D., Pach, S., & Wolber, G. (2020) · RSC Medicinal Chemistry · doi:10.1039/d0md00218f · Cited by 15
Fu, D., Shen, J., Li, W., Wang, Y., Zhong, Z., Ye, H., Huang, N., Fan, L., Yang, X., Yu, X., et al. (2021) · Blood Purification · doi:10.1159/000512962 · Cited by 17
Dietary Patterns, Gut Microbiota Remodeling, and Cardiometabolic Disease
Guiducci, L., Nicolini, G., & Forini, F. (2023) · Metabolites · doi:10.3390/metabo13060760 · Cited by 18
Li, Z., Hui, J., Li, S., Cao, T., Zhang, J., Mao, X., Wang, F., Wang, F., He, P., You, Y.-P., et al. (2022) · European Journal of Neurology · doi:10.1111/ene.15249 · Cited by 19
Blood-based biomemristor for hyperglycemia and hyperlipidemia monitoring
Gao, K., Sun, B. T., Zhou, G., Cao, Z., Xiang, L.-B., Yu, J., Wang, R., Yao, Y., Lin, F., Li, Z., et al. (2024) · Materials Today Bio · doi:10.1016/j.mtbio.2024.101169 · Cited by 14
“Persistent HGY and HLP are associated with an increased risk of cardiovascular diseases, visual impairment, and organ disorders [5,6].”
BackgroundOsborn, L. J., Orabi, D., Goudarzi, M., Sangwan, N., Banerjee, R., Brown, A. L., Kadam, A., Gromovsky, A. D., Linga, P., Cresci, G., et al. (2021) · Immunometabolism · doi:10.20900/immunometab20210029 · Cited by 15
Huang, W., Zhong, A., Xu, H., Xu, C. B., Wang, A., Wang, F., Li, X., Liu, Y., Zou, J., Zhu, H., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.761547 · Cited by 15
Association between gut microbiota and prediabetes in people living with HIV
Jayanama, K., Phuphuakrat, A., Pongchaikul, P., Prombutara, P., Nimitphong, H., Reutrakul, S., & Sungkanuparph, S. (2022) · Current Research in Microbial Sciences · doi:10.1016/j.crmicr.2022.100143 · Cited by 16
“A knockout of this gene prevented the development of hyperglycemia in the mouse model (Miao et al., 2015).”
BackgroundSignal Pathways and Intestinal Flora through Trimethylamine N-oxide in Alzheimer's Disease
Zhang, Y., & Jian, W. (2023) · Current Protein and Peptide Science · doi:10.2174/1389203724666230717125406 · Cited by 14
Flavin-Containing Monooxygenase 3 Reduces Endoplasmic Reticulum Stress in Lipid-Treated Hepatocytes
Liao, B. M., McManus, S. A., Hughes, W. E., & Schmitz‐Peiffer, C. (2016) · Molecular Endocrinology · doi:10.1210/me.2015-1217 · Cited by 14
Catucci, G., Polignano, I. L., Cusumano, D., Medana, C., Gilardi, G., & Sadeghi, S. J. (2017) · Analytical Biochemistry · doi:10.1016/j.ab.2017.01.024 · Cited by 14
A direct time-based ITC approach for substrate turnover measurements demonstrated on human FMO3
Catucci, G., Sadeghi, S. J., & Gilardi, G. (2019) · Chemical Communications · doi:10.1039/c9cc01356c · Cited by 14
Gabr, M. T., & Świderek, K. (2020) · ChemMedChem · doi:10.1002/cmdc.202000571 · Cited by 15
Huang, Y., Qin, X., Zou, J., Wu, Y., & Yu, R. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1106812 · Cited by 14
“Furthermore, inhibition of TMAO production can reduce the activation of PERK and inhibit FoxO1, which may prevent hyperglycemia (14, 15).”
BackgroundYu, X. M., Wang, Y., Yang, R., Wang, Z., Wang, X., Wang, S., Zhang, W., Dong, J., Chen, W., Ji, F., et al. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1360861 · Cited by 18
“Cardiovascular events are the primary cause of morbidity and mortality in individuals with diabetes, who have a twofold higher risk of cardiovascular events than non-diabetic individuals (3 – 5).”
BackgroundObeid, R., Awwad, H. M., Knell, A., Hübner, U., & Geisel, J. (2018) · Nutrients · doi:10.3390/nu10091209 · Cited by 13
“FMO3 (UniProt P31513) interacts with glucose metabolism [25].”
BackgroundEffect of endurance exercise training on liver gene expression in male and female mice
Melo, L., Tilmant, K., Hagar, A., & Klaunig, J. E. (2020) · Applied Physiology, Nutrition, and Metabolism · doi:10.1139/apnm-2020-0379 · Cited by 14
Mechanistic Review on the Role of Gut Microbiota in the Pathology of Cardiovascular Diseases
Usman, I., Anwar, A., Shukla, S., & Pathak, P. (2024) · Cardiovascular & Haematological Disorders - Drug Targets · doi:10.2174/011871529x310857240607103028 · Cited by 17
Xu, C., Zhang, M., Zhang, S., Wang, P., Lai, C., Meng, D., Chen, Z., Yi, X., & Gao, X. (2024) · Journal of Chromatography B · doi:10.1016/j.jchromb.2024.124210 · Cited by 12
The SNP Rs915014 in MTHFR Regulated by MiRNA Associates with Atherosclerosis
Liu, X., Wang, L., Chi, H., Wang, J., Zheng, Q., Li, J., Li, Y., & Yang, D. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000487355 · Cited by 12
Lama, S., Monda, V., Rizzo, M. R., Dacrema, M., Maisto, M., Annunziata, G., Tenore, G. C., Novellino, E., & Stiuso, P. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/2961406 · Cited by 12
“To gain an insight about the mechanism through which Taurisolo® sustained the cardiomyocyte viability, we have damaged the H9c2 cardiomioblastic cell line with high glucose concentration (44mM) and TMAO, a molecule linked to obesity and energy metabolism [23, 24] (Figure 1).”
BackgroundHana, C. A., Tran, L. V., Mölzer, C., Müllner, E., Hörmann-Wallner, M., Franzke, B., Tosevska, A., Zöhrer, P. A., Doberer, D., Marculescu, R., et al. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154913 · Cited by 14
Lee, S. J., Park, Y. S., Kim, Y. J., Han, S., Hwang, G., Han, Y., Heo, Y., Ha, E., & Ha, T. K. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10215091 · Cited by 13
“An interesting recent study showed that FMO3 is suppressed by insulin and increases in obese/insulin-resistant humans [24].”
BackgroundYu, N., Gu, N., Wang, Y., Zhou, B., Lu, D., Li, J., Ma, X., Zhang, J., & Guo, X. (2022) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s339698 · Cited by 13
Trimethylamine N-Oxide as a Potential Risk Factor for Non-communicable Diseases: A Systematic Review
Tavassol, Z. H., Ejtahed, H., Larijani, B. A., & Hasani‐Ranjbar, S. (2022) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530323666221103120410 · Cited by 12
Common Pathogenetic Pathways of Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus
Giannopoulos, C., Tzima, I. G., Tentolouris, N., & Vasileiadis, I. (2023) · Current Diabetes Reviews · doi:10.2174/1573399819666230216112032 · Cited by 14
Association between Intestinal Microecological Changes and Atherothrombosis
Zhuo, X., Luo, H., Lei, R., Lou, X., Bian, J., Guo, J., Luo, H., Zhang, X., Jiao, Q., & Gong, W. (2023) · Microorganisms · doi:10.3390/microorganisms11051223 · Cited by 12
Wang, X., Zhu, N., Jia, J., Gu, L., Du, Y. C., Tang, G., Wang, X., Yang, M. G., & Yuan, W. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119173 · Cited by 12
Huang, T., Nazir, B., Altaf, R., Zang, B., Zafar, H., Paiva‐Santos, A. C., Niaz, N., Imran, M., Duan, Y., Abbas, M., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.985857 · Cited by 12
“Several lines of evidence have also supported the role of the secondary genes FMO1 and ALOX1 having interaction with CYP3A4 and PTGS1 in diabetes mellitus (31, 32).”
BackgroundChen, Y., Huang, G., Ge, H., Zhu, Y., Yang, Y., Yu, Y., Tian, F., Gao, K., & Zhou, E. (2022) · Phytotherapy Research · doi:10.1002/ptr.7684 · Cited by 11
“…therapies primarily involve changing diet and lifestyle, adjusting the intestinal microbial communities, inhibiting the synthesis of TMA, and inhibiting the oxidation of TMA (Erickson et al., 2019; Miao et al., 2015; Park, Miller, Rhyne, Wang, & Hazen, 2019; Ryan et al., 2017; Tenore et al., 2019).”
MethodRezabakhsh, A., Habtemariam, S., Parvizi, R., Meddahi‐Pellé, A., Rodriguez‐Ruiz, V., Pavon‐Djavid, G., & Barzgari, A. (2025) · Cell Communication and Signaling · doi:10.1186/s12964-025-02335-4 · Cited by 11
“Flavin-containing monooxygenase 3 (FMO3) is a key enzyme for converting TMA to TMAO in the liver [123].”
Yuan, Y., Gan, C., Wang, M., Zou, J., Wang, Z., Li, S., & Lv, H. (2024) · Endocrine · doi:10.1007/s12020-024-03699-2 · Cited by 12
“…mechanism is: (1) Insulin resistance and the corresponding increase in plasma insulin levels in T2DM patients will increase the content of TMAO [29], high levels of TMAO promote osteoclast differentiation and induce bone loss by activating the ROS-dependent NF-κ B signaling pathway [16, 24];…”
Ng, C. Y. J., Zhong, L. L. D., Ng, H. S., Goh, K. S., & Zhao, Y. X. (2024) · Nutrients · doi:10.3390/nu16223935 · Cited by 12
Liu, Z., Zhang, C., Khodadadi‐Jamayran, A., Dang, L., Han, X., Kim, K., Li, H., & Zhao, R. (2016) · Stem Cells and Development · doi:10.1089/scd.2016.0259 · Cited by 11
“Recently, the miR-183/96/182 cluster has been demonstrated to positively regulate cholesterol biosynthesis in liver cells by inhibiting expression of ISIG2 and FBXW7 [51–53], which encode factors that negatively regulate SREBF2.”
García-Fernández, H., Alcala-Diaz, J. F., Quintana‐Navarro, G. M., López-Moreno, J., Luque-Córdoba, D., Narváez, E. R.-D., Larriva, A. P. A.-D., Gutierrez-Mariscal, F. M., Torres-Peña, J. D., Rodríguez-Cano, D., et al. (2024) · The World Journal of Men s Health · doi:10.5534/wjmh.230366 · Cited by 10
“FMO3 is also subject to metabolic regulation, as it is suppressed by insulin signaling and increases in obese insulin-resistant mice and humans where the insulin signal is impaired, or in patients with diabetes [20].”
Enzymatically Produced Trimethylamine N-Oxide: Conserving It or Eliminating It
Catucci, G., Querio, G., Sadeghi, S. J., Gilardi, G., & Levi, R. C. (2019) · Catalysts · doi:10.3390/catal9121028 · Cited by 11
Peptidomimetic‐based approach toward inhibitors of microbial trimethylamine lyases
Gabr, M. T., Deganutti, G., & Reynolds, C. A. (2020) · Chemical Biology & Drug Design · doi:10.1111/cbdd.13775 · Cited by 10
Tahara, A., Tahara, N., Yamagishi, S., Honda, A., Igata, S., Nitta, Y., Bekki, M., Nakamura, T., Sugiyama, Y., Sun, J., et al. (2017) · International Journal of Food Sciences and Nutrition · doi:10.1080/09637486.2017.1318117 · Cited by 10
“Many researchers have reported plasma levels of TMA and TMAO in humans (Lundh et al. 1995; Tang et al. 2013; Lever et al. 2014; Ufnal M et al. 2015; Malinowska et al. 2017).”
InfluentialHeath, H., DeGreef, K., Rosario, R., Smith, M., Mitchell, I., Pilolla, K. D., Phelan, S., Brito, A., & Frano, M. R. L. (2022) · Nutrition · doi:10.1016/j.nut.2022.111898 · Cited by 11
Breaking bugs: gut microbes metabolize dietary components and modulate vascular health
Babu, A. K. S., Srinivasan, H., & Babu, P. V. A. (2023) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2023.2251616 · Cited by 12
“TMA-lyase gene is over-abundant in CVD, and FMO3 is increased in diabetic patients (Miao et al. 2015; Zhao and Wang 2020).”
Huang, P., Chen, D., Chen, Y., Shih, M., Lee, B., Tain, Y., Hsieh, C., & Hou, C. (2024) · Molecules · doi:10.3390/molecules29020429 · Cited by 9
“Thus, animal models and human clinics must provide more validation of the combination of REB, ED4, and probiotics against dietary-sourced TMA, including interruption and modulation mechanisms (such as the inhibition of FMO3 and TMAO by insulin [60]).”
BackgroundDiet-mediated metaorganismal relay biotransformation: health effects and pathways
Li, Y., Cao, H., Wang, X., Guo, L., Ding, X., Zhao, W., & Zhang, F. (2021) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2021.2004993 · Cited by 9
“In the gut, succinate is a key intermediate in the microbial succinate pathway, the most common propionate generation pathway mentioned above (Miller and Wolin 1979; Reichardt et al.”
BackgroundEnvironmental biotransformation mechanisms by flavin-dependent monooxygenase: A computational study
Guo, F., Tian, Y., Ji, S., Min, H., Ding, W., Yu, H., Li, Y., & Ji, L. (2023) · Chemosphere · doi:10.1016/j.chemosphere.2023.138403 · Cited by 9
Genetic and Clinical Predictive Factors of Sulfonylurea Failure in Patients with Type 2 Diabetes
Ren, Q., Xiao, D., Han, X., Edwards, S. L., Wang, H., Tang, Y. C., Zhang, S., Li, X., Zhang, X., Cai, X., et al. (2016) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2015.0427 · Cited by 9
“39 Genetic variants have been identified in FMO2 and FMO3 , with many impacting substrate activity through loss of protein function.”
Bai, D., Li, Q., Xiong, Y., Wang, C., Shen, P., Bai, L., Lu, Y., & Wu, P. (2018) · Toxicological Sciences · doi:10.1093/toxsci/kfy104 · Cited by 8
Babu, A. K. S., Petersen, C., Paz, H. A., Iglesias‐Carres, L., Li, Y., Zhong, Y., Neilson, A. P., Wankhade, U. D., & Babu, P. V. A. (2023) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.202300386 · Cited by 9
Ma, P., Li, G., Jiang, X., Shen, X., Li, H., Yang, L., & Liu, W. (2020) · Aging · doi:10.18632/aging.202330 · Cited by 9
The carnitine degradation pathway of Acinetobacter baumannii and its role in virulence
Breisch, J., Schumm, C., Poehlein, A., Daniel, R., & Averhoff, B. (2022) · Environmental Microbiology · doi:10.1111/1462-2920.16075 · Cited by 11
Benefits and challenges of olive biophenols: a perspective
Rasouli, H., Mazinani, M. H., & Haghbeen, K. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819528-4.00045-6 · Cited by 8
Al-Busaidi, A., Alabri, O., Alomairi, J., Elsharaawy, A., Lawati, A. A., Lawati, H. A., & Das, S. (2024) · Current Diabetes Reviews · doi:10.2174/0115733998281910231231051814 · Cited by 9
Piskol, F., Neubauer, K., Eggers, M., Bode, L. M., Jasper, J., Slusarenko, A. J., Reijerse, E. J., Lubitz, W., Jahn, D., & Moser, J. (2022) · Bioscience Reports · doi:10.1042/bsr20221102 · Cited by 11
“The resulting reaction product TMA enters the host circulation and is further converted to TMAO in the liver [40,41].”
Archaebiotics: Archaea as Pharmabiotics for Treating Chronic Disease in Humans?
Hania, W. B., Ballet, N., Vandekerckove, P., Ollivier, B., O’Toole, P. W., & Brugère, J. (2017) · InTech eBooks · doi:10.5772/intechopen.69945 · Cited by 9
“Interestingly however, various mice T2D models showed that one key liver enzyme implicated in the generation of TMA (FMO3, see Section 2.3.) was regulated by insulin [ 28 ].”
InfluentialMinor diplotypes of FMO3 might protect children and adolescents from obesity and insulin resistance
Morandi, A., Zusi, C., Corradi, M., Olivieri, F., Piona, C. A., Fornari, E., & Maffeis, C. (2018) · International Journal of Obesity · doi:10.1038/s41366-018-0100-7 · Cited by 7
Population studies of TMAO and its precursors may help elucidate mechanisms
Meyer, K. A. (2020) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/nqaa068 · Cited by 7
Heianza, Y., Zhou, T., He, H., DiDonato, J. A., Bray, G. A., Sacks, F. M., & Qi, L. (2021) · International Journal of Obesity · doi:10.1038/s41366-021-00939-7 · Cited by 5
Amedei, A., Lamminpää, I., & Parolini, C. (2025) · Biomedicines · doi:10.3390/biomedicines13102428 · Cited by 6
Canyelles, M., Pérez, A., Junza, A., Miñambres, I., Yanes, Ó., Sardà, H., Rotllán, N., Julve, J., Benítez, S., Sánchez‐Quesada, J. L., et al. (2022) · Diagnostics · doi:10.3390/diagnostics12112783 · Cited by 6
Dean, Y. E., Rouzan, S. S., Pintado, J. J. L., Talat, N. E., Mohamed, A. R. H., Verma, S., Kamdi, Z. A., Gir, D., Helmy, A., Helmy, Z., et al. (2023) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000001426 · Cited by 8
“…employing genetic modi fi cations of FMO3, the primary enzyme responsible for transforming TMA into TMAO [8] , has af fi rmed the involvement of this meta-microbial pathway in the control of sterol and overall cholesterol metabolism, as well as in the formation of atherosclerotic plaque [9 – 11] .”
BackgroundMonoamine Oxidases and Flavin-Containing Monooxygenases
Cashman, J. R. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.64091-6 · Cited by 6
Battillo, D. J., & Malin, S. K. (2025) · Experimental Physiology · doi:10.1113/ep092550 · Cited by 5
TMAO Accumulation Induced by Hyperglycemia Triggers Endoplasmic Reticulum Stress in the Mouse Liver
Gao, Q., Li, T., AL‐Ansi, W., Fan, M., Qian, H., Li, Y., & Wang, L. (2025) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.70278 · Cited by 5
Trimethylamine-N-oxide: the microbial cue in immune-mediated disorders
Mirji, G., Bhat, S. A., & Shinde, R. S. (2026) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2026.02.008 · Cited by 5
Agarwal, M., Roth, K., Yang, Z., Sharma, R., Maddipati, K. R., Westrick, J. A., & Petriello, M. C. (2024) · Environmental Research · doi:10.1016/j.envres.2024.118492 · Cited by 6
Dysbiosis and Regulation of Gut Microbiota in Type 2 Diabetes Mellitus
Minakshi, Kumari, H., Prakash, S., & Kumar, A. (2024) · Current Pharmaceutical Biotechnology · doi:10.2174/0113892010318580240910061534 · Cited by 5
Mechanisms and Intervention Strategies of Trimethylamine N-Oxide in Abdominal Aortic Aneurysm
Abudureheman, D., Janaerbieke, S., Song, Y., Han, S., Yimaer, W., & Wang, H. (2025) · Cardiology · doi:10.1159/000546190 · Cited by 7
“In models of selective hepatic insulin resistance, Miao et al. observed elevated circulating TMAO levels coinciding with hepatic FMO3 upregulation – the key enzyme catalyzing TMAO biosynthesis [147].”
Relationship between Red Meat Metabolite Trimethylamine N-oxide and Cardiovascular Disease
Yousuf, A., McVey, D. G., & Ye, S. (2022) · Heart and Mind · doi:10.4103/hm.hm_8_21 · Cited by 5
Gut microbe-derived trimethylamine shapes circadian rhythms through the host receptor TAAR5
Mahen, K. K., Massey, W. J., Orabi, D., Brown, A. L., Jaramillo, T. C., Burrows, A. C., Horak, A. J., Dutta, S., Mrdjen, M., Mouannes, N., et al. (2025) · eLife · doi:10.7554/elife.107037.3 · Cited by 6
Cardiovascular–kidney–metabolic syndrome through the lens of gut‑derived uremic toxins
Xu, C., Snelson, M., & Marques, F. Z. (2026) · Gut Microbes · doi:10.1080/19490976.2026.2685906 · Cited by 4
“78 In dysregulated insulin states, a hallmark of T2D and metabolic syndrome, this regulatory control is impaired, leading to higher FMO3 activity and TMAO levels.”
Deciphering Microbial Carbohydrate Metabolism: Unveiling Mechanistic Insights Into Type 2 Diabetes
Kumar, N., Sain, S., & Solanki, B. (2025) · Advanced Gut & Microbiome Research · doi:10.1155/agm3/4395850 · Cited by 5
“In insulin-resistant mice, knocking down Fmo3 was shown to prevent these metabolic disturbances [94].”
In Vivo and In Vitro Pharmacokinetic Studies of a Dual Topoisomerase I/II Inhibitor
Hildebrandt, J., Bauerschlag, D., Fricker, G., Girreser, U., Konukiewitz, B., Kellers, F., Maass, N., Clement, B., & Flörkemeier, I. (2025) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.4c00596 · Cited by 5
Yang, X., Zhang, X., Sun, C., Zhao, C., Kong, X., Zhao, M., Ji, L., & Li, Y. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1575087 · Cited by 4
Flavin-containing Monooxygenases in the Brain and their Involvement in Neurodegeneration and Aging
Li, B., & An, Z. (2023) · Journal of Exploratory Research in Pharmacology · doi:10.14218/jerp.2022.00067 · Cited by 4
Metadata
- Authors
- Miao, J., Ling, A. V., Manthena, P. V., Gearing, M. E., Graham, M. J., Crooke, R. M., Croce, K. J., Esquejo, R. M., Clish, C. B., Morbid Obesity Study Group, Torrecilla, E., Vázquez, G. F., Rubio, M. A., Cabrerizo, L., Barabash, A., Pernaute, A. S., Torres, A. J., Vicent, D., & Biddinger, S. B.
- Affiliations
- Boston Children's Hospital (US)
- Ionis Pharmaceuticals (United States) (US)
- Brigham and Women's Hospital (US)
- Sanford Burnham Prebys Medical Discovery Institute (US)
- Broad Institute (US)
- Carlos III Hospital (ES)
- Hospital Clínico San Carlos (ES)
- Universidad Complutense de Madrid (ES)
- Corresponding author
- Biddinger, Sudha B.
- ORCID
- Venue
- Nature Communications
- Published
- 2015-04-07
- Volume
- 6
- Issue
- 1
- Pages
- 6498-6498
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC4391288
- OpenAlex
- W2094278898
- Cited by
- 368
- References
- 58
- Citations by year
- 2026: 16 · 2025: 29 · 2024: 26 · 2023: 35 · 2022: 41 · 2021: 40 · 2020: 44 · 2019: 30 · 2018: 33 · 2017: 29 · 2016: 35 · 2015: 9
- FWCI
- 30.96
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- American Heart Association
- Brigham and Women's Hospital
- Wake Forest University
- Broad Institute
- Institut National de la Santé et de la Recherche Médicale
- Sociedad de Endocrinología, Nutrición y Diabetes de la Comunidad de Madrid
- National Heart, Lung, and Blood Institute (R01HL048044, HL48044, HL109650, R01HL109650)
- National Institute of Diabetes and Digestive and Kidney Diseases (L40 DK065607, K99DK100539, DK-100539, R00DK100539)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Keywords
- FMO3, insulin resistance, diabetes-associated atherosclerosis, trimethylamine N-oxide, FOXO1, obesity, hyperglycemia, hyperlipidemia, metabolic dysfunction, insulin signaling
- MeSH terms
- Forkhead Box Protein O1, Animals, Diabetes Mellitus, Type 2, Humans, Hyperglycemia, Hyperlipidemias, Hypoglycemic Agents, Insulin, Insulin Resistance, Cholesterol, HDL, Cholesterol, LDL, Liver, Male, Obesity, Oxygenases, RNA, Messenger, Triglycerides, Blotting, Western, Rats, Sprague-Dawley, Gene Expression Profiling, Hepatocytes, Atherosclerosis, Mice, Rats, Forkhead Transcription Factors, Gene Knockdown Techniques, Real-Time Polymerase Chain Reaction, In Vitro Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.